Why spotting it early is so hard
Sepsis (a life-threatening response to infection) is already one of the most complex medical emergencies. When it triggers coagulopathy (a breakdown of the blood's clotting system), the situation becomes even more dangerous. Blood clots can form in small vessels throughout the body, cutting off oxygen to vital organs. At the same time, the body can run out of clotting proteins, causing uncontrolled bleeding. It is a dangerous paradox — too much clotting and not enough.
Right now, doctors rely on a mix of lab tests and clinical scores to track sepsis patients. But catching the specific moment when clotting starts to go wrong has remained frustratingly difficult. That means treatment often comes too late.
What the old playbook missed
Doctors have long used general markers of inflammation and infection — like C-reactive protein (CRP) and procalcitonin — to track how sick a patient is. These tests are useful, but they don't tell you much about what's happening specifically inside the blood's clotting system.
But here's the twist: this new analysis found that several other markers, some not routinely tested in most hospitals, may actually give a much clearer warning that SIC is developing.
A signal hiding in the bloodstream
Think of the inner lining of your blood vessels as a protective coating — a gel-like layer called the glycocalyx (pronounced gly-co-KAY-lix). When this coating starts to break down, it's like peeling the rubber off a garden hose. Everything becomes more leaky and reactive. Glycocalyx degradation emerged as the strongest single predictor in this analysis, with patients showing its breakdown having nearly 12 times higher odds of developing SIC.
Other key signals included low levels of fibrinogen (a protein that helps form clots), low albumin (a blood protein that keeps fluid in vessels), and rising lactate (a sign tissues aren't getting enough oxygen). Microscopic cell fragments called microparticles, and a protein called thrombomodulin released by damaged vessel walls, were also linked to higher SIC risk.
Researchers pooled data from 34 studies covering 37,459 patients — one of the largest analyses ever done on this topic. They used statistical methods to combine results from different hospital settings and patient types, looking for which markers consistently appeared before SIC developed.
The findings were striking. Glycocalyx breakdown was by far the most powerful predictor. Low fibrinogen came next, with patients showing low levels having more than four times the odds of developing SIC. Reduced albumin, elevated lactate, and the presence of neutrophil extracellular traps (sticky webs that immune cells cast to trap bacteria, but which can also trigger clotting) all showed meaningful associations as well.
These findings do not mean doctors should immediately add all these tests to every sepsis patient's workup.
The associations are real and consistent, but the research design — combining many different studies — can't prove that any single marker directly causes SIC. It only shows that the two tend to occur together.
The bigger picture
This research fits into a growing effort to personalize care for sepsis patients. The medical community increasingly recognizes that sepsis is not one disease but many, and that different patients need different approaches. Identifying who is most at risk for coagulopathy could help doctors intervene earlier — with treatments like anticoagulants or blood products — before organ damage becomes irreversible.
If you or a loved one is hospitalized with a serious infection, this research isn't something to act on directly right now. These markers are not yet part of standard clinical guidelines for SIC. But it's reasonable to ask your care team how they are monitoring clotting function, especially in an ICU setting. Awareness of this evolving evidence can help you ask better questions.
This was a meta-analysis — a study of studies — which means the quality of the data depends on the quality of the original research. The included studies varied in design, patient populations, and how they measured these markers. The researchers note that the associations found should not be interpreted as direct cause-and-effect. Larger, prospective trials (studies that follow patients forward in time with standardized protocols) are needed to confirm which markers are most useful in real clinical practice.
The next step is designing prospective trials that test these specific markers in real-time, with standardized cutoffs that doctors can actually use at the bedside. If even one or two of these markers prove reliable in well-designed trials, it could change how intensive care units screen for SIC — catching the clotting crisis before it cascades. That work is underway in several research centers, and results could begin shaping clinical guidelines within the next several years.
